# Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

> **NCT07325435** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **MaryAnn Banerji** · enrollment: 60 (estimated)

## Conditions studied

- Type 2 Diabetes (T2DM)

## Interventions

- **DRUG:** SGLT-2 inhibitor
- **DRUG:** GLP1-RA

## Key facts

- **NCT ID:** NCT07325435
- **Lead sponsor:** MaryAnn Banerji
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-21
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07325435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07325435, "Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07325435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*